Saturday, September 09, 2017 12:11:08 PM
Hopefully $ELTP shareholders realize that the Percocet review by the FDA is a normal review taken when the FDA has signaled that they are proceeding to approve the ANDA drug.
New Commissioner Gottlieb has his guidelines and he is most definitely imposing these guidelines as the new Sheriff in town.
The FDA CR Minor Amendment received by $ELTP for Percocet will NOT delay their Percocet approval timeline. While $ELTP filed Percocet on Aug 10,2016 the FDA did not look at it until Nov 2016 and then awarded it for preliminary approval and a go forward with it.
IMO a Oct/Nov 2017 FDA approval, which would be 12 months since the FDA preliminary approval on Nov 2016, is a very likely scenario.
Acetaminophen API storage, handling, and documentation is of concern because of its chemical properties and Gottlieb may be imposing higher requirements, concerning Temperature, Humidity, and Documentation control.
Paracetamol
https://en.wikipedia.org/wiki/Paracetamol
New Commissioner Gottlieb has his guidelines and he is most definitely imposing these guidelines as the new Sheriff in town.
The FDA CR Minor Amendment received by $ELTP for Percocet will NOT delay their Percocet approval timeline. While $ELTP filed Percocet on Aug 10,2016 the FDA did not look at it until Nov 2016 and then awarded it for preliminary approval and a go forward with it.
IMO a Oct/Nov 2017 FDA approval, which would be 12 months since the FDA preliminary approval on Nov 2016, is a very likely scenario.
Acetaminophen API storage, handling, and documentation is of concern because of its chemical properties and Gottlieb may be imposing higher requirements, concerning Temperature, Humidity, and Documentation control.
Paracetamol
https://en.wikipedia.org/wiki/Paracetamol
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
